|
| 37379584 | HIV-Positive Liver Transplant Does not Alter the Latent Viral Reservoir in Recipients With Antiretroviral Therapy-Suppressed HIV. | J Infect Dis | 2023 |
| 37463049 | The latent reservoir of inducible, infectious HIV-1 does not decrease despite decades of antiretroviral therapy. | J Clin Invest | 2023 |
| 36763044 | Varied Patterns of Decay of Intact Human Immunodeficiency Virus Type 1 Proviruses Over 2 Decades of Antiretroviral Therapy. | J Infect Dis | 2023 |
| 37126090 | Current HIV/SIV Reservoir Assays for Preclinical and Clinical Applications: Recommendations from the Experts 2022 NIAID Workshop Summary. | AIDS Res Hum Retroviruses | 2023 |
| 36448802 | The BCL-2 Inhibitor Venetoclax Augments Immune Effector Function Mediated by Fas Ligand, TRAIL, and Perforin/Granzyme B, Resulting in Reduced Plasma Viremia and Decreased HIV Reservoir Size during Acute HIV Infection in a Humanized Mouse Model. | Journal of Virology | 2022 |
| 36345940 | The effect of induction immunosuppression for kidney transplant on the latent HIV reservoir. | JCI Insight | 2022 |
| 34901797 | Single center, open label dose escalating trial evaluating once weekly oral ixazomib in ART-suppressed, HIV positive adults and effects on HIV reservoir size in vivo. | eClinicalMedicine | 2021 |
| 34162752 | The TLR7 agonist vesatolimod induced a modest delay in viral rebound in HIV controllers after cessation of antiretroviral therapy. | Sci Transl Med | 2021 |
| 33043969 | Vesatolimod, a Toll-like Receptor 7 Agonist, Induces Immune Activation in Virally Suppressed Adults Living With Human Immunodeficiency Virus-1. | Clinical Infectious Diseases | 2021 |
| 32823274 | Selective Decay of Intact HIV-1 Proviral DNA on Antiretroviral Therapy. | J Infect Dis | 2021 |
| 33037877 | Nonstructured Treatment Interruptions Are Associated With Higher Human Immunodeficiency Virus Reservoir Size Measured by Intact Proviral DNA Assay in People Who Inject Drugs. | J Infect Dis | 2021 |
| 33269401 | Similar Frequency and Inducibility of Intact Human Immunodeficiency Virus-1 Proviruses in Blood and Lymph Nodes. | J Infect Dis | 2021 |
| 33115867 | Shared Mechanisms Govern HIV Transcriptional Suppression in Circulating CD103[+] and Gut CD4[+] T Cells. | J Virol | 2020 |
| 31895150 | Elite suppressors have low frequencies of intact HIV-1 proviral DNA. | AIDS | 2020 |
| 32045386 | Differential decay of intact and defective proviral DNA in HIV-1-infected individuals on suppressive antiretroviral therapy. | JCI Insight | 2020 |
| 32690683 | Intact proviral DNA assay analysis of large cohorts of people with HIV provides a benchmark for the frequency and composition of persistent proviral DNA. | Proc Natl Acad Sci U S A | 2020 |
| 32848246 | Distinct viral reservoirs in individuals with spontaneous control of HIV-1. | Nature | 2020 |
| 31295427 | The Landscape of Persistent Viral Genomes in ART-Treated SIV, SHIV, and HIV-2 Infections. | Cell Host Microbe | 2019 |
| 30700913 | A quantitative approach for measuring the reservoir of latent HIV-1 proviruses. | Nature | 2019 |
| 29433524 | Measuring replication competent HIV-1: advances and challenges in defining the latent reservoir. | Retrovirology | 2018 |
| 30232425 | The role of CD32 during HIV-1 infection. | Nature | 2018 |
| 27898590 | Reactivation of simian immunodeficiency virus reservoirs in the brain of virally suppressed macaques. | AIDS | 2017 |
| 28656019 | Characterization of Elite Suppressors Cell-Associated HIV-1 mRNA at Baseline and with T Cell Activationâ¿©â¿©. | Yale J Biol Med | 2017 |
| 29045905 | Transcriptional Reprogramming during Effector-to-Memory Transition Renders CD4<sup>+</sup> T Cells Permissive for Latent HIV-1 Infection. | Immunity | 2017 |
| 26714716 | Measuring the Frequency of Latent HIV-1 in Resting CD4⺠T Cells Using a Limiting Dilution Coculture Assay. | Methods Mol Biol | 2016 |
| 26035316 | Medroxyprogesterone acetate increases HIV-1 infection of unstimulated peripheral blood mononuclear cells in vitro. | AIDS | 2015 |
| 25822022 | Ex vivo analysis identifies effective HIV-1 latency-reversing drug combinations. | J Clin Invest | 2015 |
| 24658076 | New ex vivo approaches distinguish effective and ineffective single agents for reversing HIV-1 latency in vivo. | Nat Med | 2014 |
| 24275119 | A novel cell-based high-throughput screen for inhibitors of HIV-1 gene expression and budding identifies the cardiac glycosides. | J Antimicrob Chemother | 2014 |
| 24713404 | Role of autophagy genetic variants for the risk of Candida infections. | Med Mycol | 2014 |
| 24799684 | Measuring reversal of HIV-1 latency ex vivo using cells from infected individuals. | Proc Natl Acad Sci U S A | 2014 |
| 23737751 | Rapid quantification of the latent reservoir for HIV-1 using a viral outgrowth assay. | PLoS Pathog | 2013 |
| 23979165 | Multi-step inhibition explains HIV-1 protease inhibitor pharmacodynamics and resistance. | J Clin Invest | 2013 |
| 24177428 | CX3CR1-dependent renal macrophage survival promotes Candida control and host survival. | J Clin Invest | 2013 |
| 23536672 | A novel PCR assay for quantification of HIV-1 RNA. | J Virol | 2013 |
| 22144535 | Cytokine gene polymorphisms and the outcome of invasive candidiasis: a prospective cohort study. | Clin Infect Dis | 2012 |
| 22301633 | Toll-like receptor 1 polymorphisms increase susceptibility to candidemia. | J Infect Dis | 2012 |
| 21881131 | Genetic variation in the dectin-1/CARD9 recognition pathway and susceptibility to candidemia. | J Infect Dis | 2011 |
| 20671299 | Lipidomics reveals a remarkable diversity of lipids in human plasma. | J Lipid Res | 2010 |